- Novavax, Inc. specializes in developing innovative vaccines, including its COVID-19 vaccine Nuvaxovid, and reported total revenue of $1.1 billion for the full year 2025, positioning itself as a significant player in the pharmaceutical industry.
- In the past year, Novavax signed a non-exclusive licensing agreement with Pfizer for its Matrix-M® adjuvant technology and achieved $225 million in milestones from its partnership with Sanofi, reflecting strong business development efforts.
- The company has entered multiple Material Transfer Agreements with major global pharmaceutical companies to explore the utility of its Matrix-M technology, indicating a robust collaborative approach to vaccine development.
- Ideal buyers for Novavax's products include large pharmaceutical companies and healthcare providers looking for innovative vaccine solutions, particularly as they address ongoing infectious disease challenges and regulatory uncertainties in the vaccine market.
Engineering is the company’s largest team at 217 employees, reflecting the technical resources required for process development and manufacturing. Business Management (103) and Operations (98) round out the next-largest groups, providing program oversight and day-to-day production support. Finance & Administration (76) and Sales & Support (69) supply the financial controls and customer-facing expertise needed to commercialize products, while specialized areas such as Healthcare, Risk & Compliance, Quality, and Marketing & Product collectively account for more than 180 professionals. Overall hiring of 21 employees and 102 departures were spread across these functions, indicating selective expansion and realignment rather than broad-based growth.
Employee locations show a strong Mid-Atlantic footprint. Roughly one in six team members work in Washington, DC (139), and Gaithersburg, MD (98) hosts a significant contingent near the company’s headquarters and R&D facilities. Additional clusters are found in Rockville, Frederick, Germantown, and Bethesda, illustrating the concentration of life-science talent along the I-270 biotechnology corridor. Smaller groups operate in New York, Philadelphia, Chicago, and other locations, while 462 employees are classified under “Other,” a category that captures remote staff and international sites supporting global clinical and commercial activities.
